Corporate Governance

 

An effective Corporate Governance is crucial for the management of a company’s business affairs as well as for capital market communication. This has always been of utmost significance to Evotec. Our commitment to complying with high Corporate Governance standards is our chance to:

  • Demonstrate our dedication to well-balanced and transparent rules to the market participants and to
  • Internally emphasise the importance of our clearly defined management tools and responsibilities.

 

Declaration of Compliance by the Management Board and Supervisory Board with the German Corporate Governance Code for the year 2019 as required under sec. 161 of the German Stock Corporation Act (AktG)

The German Corporate Governance Code in its current version as of 07 February 2017 (the ‘Code’) sets forth substantial legal requirements for the management and supervision of listed German companies. The rules are based to a large extent on internationally recognized standards for sound and responsible company management.

The general key principles of sound Corporate Governance are: observance of shareholder and employee interests, effective cooperation between the Management Board and the Supervisory Board and open and transparent communication.

With the following exceptions, Evotec complies with all recommendations of the Code and the majority of the Code’s suggestions. In December 2019, Evotec’s Management Board and Supervisory Board declared in accordance with Section 161 of the German Stock Corporation Act (AktG):

Evotec AG has complied in 2019 with the recommendations of the Governmental Commission on the German Corporate Governance Code (the “Code”) as published in the official section of the Federal Gazette and intends to comply in the future with the recommendations of the Code, with the following exceptions:

  • Pursuant to Section 4.2.3 of the Code, the monetary remuneration of the Management Board members comprises fixed and variable components. Variable remuneration components consist of a one-year variable remuneration determined by a bonus scheme and a long-term so-called Share Performance Plan scheme approved by the Annual General Meetings 2012, 2015 and 2017. The Share Performance Plans have a multiple-year assessment basis that has essentially forward-looking characteristics, whereas the bonus scheme is based on the achievement of certain strategic targets set by the Supervisory Board for a certain financial year.
  • The Share Performance Plans comply with the recommendations set forth in Section 4.2.3 of the Code. In particular, they refer to specific key performance indicators and define a “Maximum Target”. However, as the issuance of awards under the Share Performance Plans 2012 and 2015 after the four-year vesting period is effected in shares, there is a cap for the number of awards upon allocation, but no other cap for the value of the allocated shares. That value will only be determined by the share price at that time. The Share Performance Plan 2017 has introduced a cap with a maximum level of 350% of the contractual issue value and therefore complies in all respects with the Code.
  • Stock options issued in existing stock option programmes before their replacement by the Share Performance Plans remain valid. While the exercise of options under these stock option programmes requires an increase of the share price, the exercise is not related to other relevant comparison parameters as recommended in Section 4.2.3 of the Code. This decision is based on the lack of relevant comparison benchmarks in the field of German Biotech at the time when the stock option programmes were created.
  • The Company’s D&O insurance and the deductible for members of the Management Board contained therein are in line with Section 3.8 of the Code and with the regulations of the Act on the Appropriateness of Management Board Compensation (VorstAG) that was enacted in 2009. However, for members of the Supervisory Board, the D&O insurance contains a “reasonable” deductible as foreseen by the version of the Code in force before its version published on 05 August 2009. The Company has decided to maintain this reasonable deductible. This decision was made in view of the Company’s interest to attract international expertise for its Supervisory Board and the fact that a deductible for non-executive directors is not very common in international practice. Whilst a lot of the German companies quoted on the TecDAX do not have a respective deductible at all, the Company believes that a reasonable deductible is a good compromise.

Hamburg, December 2019

Management Board            Supervisory Board

 

German Corporate Governance Code

The German Corporate Governance Code (the “Code”) presents essential statutory regulations for the management and supervision (governance) of German listed companies and contains internationally and nationally recognised standards for good and responsible governance. The Code aims at making the German Corporate Governance system transparent and understandable. Its purpose is to promote the trust of international and national investors, customers, employees and the general public in the management and supervision of listed German stock corporations.

Declaration of Corporate Management (§§ 289f, 315d HGB)

The actions of Evotec SE’s management and oversight bodies are determined by the principles of good and responsible Corporate Governance. In this declaration, the Management Board – also acting on behalf of the Supervisory Board – provides its report on corporate management in the Group pursuant to sections 289f, 315d of the German Commercial Code (HGB) and pursuant to subsection 3.10 of the German Corporate Governance Code. Our aim is to present our corporate management principles as clearly and concisely as possible.

Declaration of compliance and reporting on Corporate Governance

Declaration of compliance

With the following exceptions, Evotec complies with all recommendations of the Code and also with the majority of the Code’s suggestions. In December 2019, Evotec’s Management Board and Supervisory Board declared in accordance with Section 161 of the German Stock Corporation Act (AktG):  

"Evotec SE has complied in 2019 with the recommendations of the Governmental Commission on the German Corporate Governance Code (the “Code”) as published in the official section of the Federal Gazette and intends to comply in the future with the recommendations of the Code, with the following exceptions:  

  • Pursuant to Section 4.2.3 of the Code, the monetary remuneration of the Management Board members comprises fixed and variable components. Variable remuneration components consist of a one-year variable remuneration determined by a bonus scheme and a long-term so-called Share Performance Plan scheme approved by the Annual General Meetings 2012, 2015 and 2017. The Share Performance Plans have a multiple-year assessment basis that has essentially forward-looking characteristics, whereas the bonus scheme is based on the achievement of certain strategic targets set by the Supervisory Board for a certain financial year.
  • The Share Performance Plans comply with the recommendations set forth in Section 4.2.3 of the Code. In particular, they refer to specific key performance indicators and define a “Maximum Target”. However, as the issuance of awards under the Share Performance Plans 2012 and 2015 after the four-year vesting period is effected in shares, there is a cap for the number of awards upon allocation, but no other cap for the value of the allocated shares. That value will only be determined by the share price at that time. The Share Performance Plan 2017 has introduced a cap with a maximum level of 350% of the contractual issue value and therefore complies in all respects with the Code.
  • Stock options issued in existing stock option programmes before their replacement by the Share Performance Plans remain valid. While the exercise of options under these stock option programmes requires an increase of the share price, the exercise is not related to other relevant comparison parameters as recommended in Section 4.2.3 of the Code. This decision is based on the lack of relevant comparison benchmarks in the field of German Biotech at the time when the stock option programmes were created. 
  • The Company’s D&O insurance and the deductible for members of the Management Board contained therein are in line with Section 3.8 of the Code and with the regulations of the Act on the Appropriateness of Management Board Compensation (VorstAG) that was enacted in 2009. However, for members of the Supervisory Board, the D&O insurance contains a “reasonable” deductible as foreseen by the version of the Code in force before its version published on 05 August 2009. The Company has decided to maintain this reasonable deductible. This decision was made in view of the Company’s interest to attract international expertise for its Supervisory Board and the fact that a deductible for non-executive directors is not very common in international practice. Whilst a lot of the German companies quoted on the TecDAX do not have a respective deductible at all, the Company believes that a reasonable deductible is a good compromise."

The current Declaration of Compliance with the German Corporate Governance Code and the declarations of the past five years can be found on Evotec’s website (www.evotec.com) in the Invest section.

Relevant management practices and compliance

Relevant management practices

Evotec takes its Corporate Governance responsibilities very seriously. As a consequence of its shares’ listing at the Frankfurt Stock Exchange and its international shareholder base, the Company recognises not only German but also international Corporate Governance standards. Evotec’s Management and Supervisory Boards are convinced that complying with rigorous Corporate Governance standards is of great benefit to the Company. It includes integrity in the dealings with employees, business associates, shareholders and the public, expressed in Evotec’s own exemplary conduct. As a service provider, Evotec has to win and retain the trust of its customers and business associates through impeccable behaviour. The Group’s aim is to be credible, solid and reliable and act accordingly. Thus Evotec regularly reviews and enhances its Corporate Governance practices.

Within the frame of strategical determination by the Management Board, specific goals are established and communicated. To accomplish our targets, we rely on the enterprise and initiative of our managers and employees. We achieve consensus on clearly defined objectives, and we regularly monitor how well we are meeting them. These agreements on aims are a fundamental component of our leadership philosophy and a crucial element of our remuneration system.

Code of conduct

Evotec’s corporate culture is committed to the highest standards of openness, integrity and accountability. A key element of integrity is compliance, which means adherence to both, the applicable laws and Company’s internal policies. Evotec’s commitment to a compliance-oriented culture is reflected in the Company’s Code of Conduct, which stipulates fundamental ethical principles, such as integrity and professionalism, that apply to board members and other employees alike.

The Code of Conduct sets standards for:

  • Accounting and the permissible use of the Company’s funds and assets;
  • Anti-money laundering principles; 
  • Compliance with insider trading laws and prevention of conflicts of interest;
  • Compliance with antitrust legislation;
  • Compliance with anti-corruption laws and associated internal guidelines;
  • A work environment free of any form of discrimination and harassment;
  • Health & safety and environmental aspects;
  • Animal welfare;
  • Non-disclosure and protection of intellectual property and business secrets;
  • Global trade; and
  • The duty to report upon the suspicion of an infringement of the Code of Conduct (whistle-blowing).

Evotec does not tolerate any violation of applicable laws or internal policies.

The Code of Conduct has been revised in the course of 2019 and is published on the Evotec website (www.evotec.com) in the Invest section.

Compliance organisation

The Compliance Programme of Evotec SE is overseen by the Company’s Compliance Officer, functioning as an independent and objective body that reviews and evaluates compliance issues/concerns within the organisation and is regularly trained via a group-wide electronic Compliance Training or face-to-face trainings tailored to the specific compliance issues and associated risks at the Company. The aim is to maintain permanent compliance awareness within all areas of Evotec’s business to ensure that any decision is in line with Evotec’s compliance best practices and to mitigate compliance risks. Said training is mandatory for all board members and other employees. The Company’s Compliance Officer monitors the participation in the training at regular intervals.

The Compliance Office helps to communicate the values underlying the Code of Conduct and anchor them firmly in the Group. It ensures Group-wide implementation of the Compliance Programme.

Another important aspect of accountability and transparency is a mechanism to enable all Evotec employees and business partners to voice concerns in a responsible and effective manner. Suspected compliance violations can be reported to an employee’s responsible line manager, the Company’s Compliance Officer or may also be reported to a worldwide compliance (whistle-blowing) hotline which is available 24 hours a day, 7 days a week. In case that a suspected compliance violation would affect a member of the Management Board, such report would be addressed to the Supervisory Board. In 2019, no reports via the central compliance hotline were registered. 

Further information can be found in Non-financial Group Report in accordance with section 289c and section 315c of the German Commercial Code. This report can be found on Evotec’s website in the Invest section under Financial Publications.

Evotec also complies with the financial market rules. The Company maintains an ad hoc Committee, which consists of the Chief Financial Officer, the General Counsel, the Head of Investor Relations and the assistant to the Board. This committee examines the ad hoc relevance of insider information and ensures that Evotec complies with the law.

Sustainability

For Evotec, sustainability plays an essential role in the Company’s business and attitude. Consequently, Evotec sets out its values and economic, ecological and social responsibility. All three criteria are reflected in Evotec’s strategy and firmly established in its business processes. Evotec pursues a business model that aims at sustainable growth, creating value for all stakeholders and protecting the interests of its shareholders. Taking responsibility for the Company’s employees and business partners and maintaining its commitment to society and a healthy environment are two of Evotec’s guiding principles.

Awareness about and reduction of the environment footprint of the Company is a key issue which currently is under further review about how Evotec can even more improve its contribution to secure our all environment and apply preserving consumption of resources (see also Non-financial Group Report/EVOChallenge). In its R&D activities, Evotec adheres to the highest scientific and ethical principles.

Further information can be found in Evotec’s separate Non-financial Group Report (Corporate Social Responsibility Report) in accordance with section 289c and section 315c of the German Commercial Code. This report can be found on Evotec’s website in the Invest section under Financial Publications.

Diversity

With regard to gender diversity, 55% of Evotec’s global workforce are women. On SE level, Evotec has achieved its gender targets set in 2015 on all levels (Supervisory Board, Management Board and the next two management levels), such as target quota of at least 30% for female Supervisory Board members, 0% for the Management Board (due to current set up of management team) and minimum 30% for the next two management levels. The Company has confirmed these objectives in 2017 going forward.

Risk management

An important element of sound Corporate Governance is dealing responsibly with risks. Evotec has established a risk and opportunities management system that enables the Management Board to detect and react to relevant risks and market developments in good time. The Management Board reports on these to the Supervisory Board. The Company’s risk and opportunities management system and policies are covered by the annual audit of financial statements. Details can be found in the Management Report on page 60 of the Evotec Annual Report and under www.evotec.com, Invest section. It also contains the report on the accounting-related internal control and risk management system required in accordance with the German Accounting Modernisation Act (BilMoG).

These systems are continually developed, adjusted to match changes in overall conditions and reviewed by the auditors. The Management Board regularly informs the Supervisory Board about existing risks and the development of these risks.

Transparency

Evotec SE informs its shareholders, financial analysts, the media and the public on a regular basis about its progress. In doing so, the Company complies with all requirements of the Code regarding transparency, timeliness, openness and shareholder equality. Evotec is committed to fair disclosure of information and its communication is governed by a Company Disclosure Policy. It is a prime concern of the Company that all relevant target groups receive the same information at the same time, and this implies communicating in both English and German. The Company’s publications are available on its website www.evotec.com in the Invest section.

This section of Evotec’s website maintains information such as news releases, the financial calendar containing the publication dates of the financial statements, investor relations conferences, annual and quarterly reports, other regulatory news and regularly updated corporate governance information. This section of the website also includes the Articles of Association, the Rules of Procedure of the Supervisory Board, the Audit Committee Charter, the Code of Conduct, the Insider Trading Policy and all declarations of compliance.

Moreover, the Company website at www.evotec.com provides comprehensive information on the Evotec Group and the Evotec share.

Accounting and auditing

On a regular basis, Evotec provides financial and business information to its shareholders and other interested parties by publishing its annual Consolidated Financial Statements, the half-year report and quarterly interim statements. As an incorporated company, whose registered head office is located within the European Union, Evotec SE must prepare and publish Consolidated Financial Statements in accordance with the International Financial Reporting Standards (IFRS) whilst observing Section 315a HGB (German Commercial Code). The Consolidated Financial Statements of the Evotec Group and the financial statements of Evotec SE are audited by the audit firm and the Supervisory Board. The audit firm is appointed by the shareholders at the Annual General Meeting and commissioned by the Supervisory Board. It participates at the Supervisory Board’s deliberations on the financial statements and reports the most significant results of its audit. The Audit Committee uses this information as a guideline for its own evaluation of the statements and reports.

The disclosed financial statements and the management reports for Evotec SE, as well as the Consolidated Financial Statements together with the consolidated management report of the Evotec Group, are audited by Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg. These audits also covered risk management and compliance with reporting requirements concerning corporate governance pursuant to section 161 of the German Stock Corporation Act. Following its consultations, the Supervisory Board also approves the financial statements and the Consolidated Financial Statements.

Working methods of the Management Board and Supervisory Board

Composition and working methods of the Management Board and Supervisory Board

As part of its conversion process from a German Stock Corporation (“AG”) to a European Company (Societas Europaea, “SE”), Evotec has decided to maintain its two-tier system with clear separation of management through the Management Board (“Vorstand”), and control through the Supervisory Board (“Aufsichtsrat”). The Management Board is responsible for managing Evotec and representing the Company in its dealings with third parties, while the Supervisory Board appoints and dismisses the members of the Evotec Management Board and oversees the management of the Company. German law prohibits the Supervisory Board from making operational management decisions. The two boards, however, work closely together to secure long-term and sustainable growth for the Company and to create shareholder value. They agree on the Company’s strategy and on business transactions, which are significant. The Annual General Meeting (“AGM”; “Hauptversammlung”) is the Company’s body representing the interests of the shareholders.

Management Board (“Vorstand”)

The Management Board of Evotec SE is responsible for the day-to-day operations of the Company and is supported by the Management Team. In its business operations and decisions, the Management Board acts on behalf of the Company and works towards its progress with the objective of sustainable creation of value, thus taking into account the interests of the shareholders, the employees and other stakeholders. The Management Board is appointed by the Supervisory Board.

The Company’s rules of internal procedure assign functional duties and responsibilities to the Management Board members. The CEO is functionally responsible for the areas of Corporate Development including M&A, Human Resources, Marketing, Investor Relations and Corporate Communications, the CFO for Finance, Controlling, Risk Management, Information Technology & Business Applications, Legal & Compliance, Procurement & Logistics, Facility Management and Equity, the COO for Evotec’s EVT Execute segment, Alliance management, Business Development, global operations plus Quality and Environment, Health and Safety (EHS), and the CSO for Evotec’s EVT Innovate segment, Evotec BRIDGEs and Intellectual Property. 

Under Evotec’s Articles of Association, the Supervisory Board determines the size of the Management Board, which must have at least one member under the German Stock Corporation Act. The Evotec Management Board consists, in addition to the CEO, of three further board members. In accordance with a suggestion of the Code, new members are appointed for up to three years; however, prolongations of existing contracts might be up to five years as currently agreed with the Chief Executive Officer and for its new contract with the Chief Scientific Officer. Management Board members may be reappointed and may be dismissed with good cause prior to the termination of their terms of office. At the ordinary Supervisory Board meetings, the Supervisory Board regularly receives information from the Management Board on possible succession planning and possible candidates. In addition, the Supervisory Board discusses succession planning at the meeting of the Nomination Committee even without the presence of the Management Board.

Members of Evotec’s Management Board have not accepted more than a total of three Supervisory Board mandates in non-Group listed companies or in supervisory bodies of companies with similar requirements. The Articles of Association can be found on Evotec’s website under www.evotec.com in the Invest section.

With regards to diversity within the Management Board, it has to be taken into account that Evotec works in a globalised industry and has a broad and international customer base. Therefore, the Supervisory Board selects Management Board members regardless of gender, nationality or age; instead, the focus lies on their qualifications and work experience only. The Supervisory Board has not yet set an age limit for members of the Management Board. However, the age of all current members of the Executive Board of Evotec SE is well below 60 years. However, for the first time in 2015, the Supervisory Board, in accordance with Section 111, section 5 of the German Stock Corporation Act (AktG), has set a gender quota of 0 percent for the Management Board. This target quota was confirmed in 2017 for a further five-year period due to the current term of the contracts of the currently active Management Board members. Currently, two out of four members of the Management Board are non-German.

The activities of the Management Board are regulated by its internal Rules of Procedure, which set out the matters reserved for the full Management Board, the responsibilities of the areas of responsibility and the majorities necessary for passing resolutions.

Meetings of the Management Board shall be called by the Chairman of the Board. Each member of the Management Board may request that an extraordinary meeting of the Management Board be called outside its regular meetings. The board meetings are chaired by the Chairman of the Management Board, who also coordinates the areas of responsibility. Persons who are not board members can, if so resolved by the Management Board, be admitted to board meetings in a consultative capacity.

Brief minutes have to be made of material discussions and resolutions. Resolutions of the Management Board will be carried regularly at its meetings. Resolutions may also be carried without a meeting, however, in writing, by telex or by telephone. The Management Board shall be quorate if a majority of its Members vote on a resolution. Resolutions of the Management Board shall be passed by a simple majority. Should there be a tie, the CEO shall decide. 

The Management Board also provides continuous updates to the Supervisory Board through regular verbal and written reports that includes in depth analysis of the status of operations. The information provided includes written monthly management reports with extensive coverage of the Company’s financial figures for the previous month, accompanied by detailed comments and explanatory text. In addition, the Management Board must submit a budget for the following fiscal year and a plan for the medium term to the Supervisory Board. The Management Board is also required to report to the Supervisory Board in a timely fashion on any transactions that may be significant with respect to the profitability or liquidity of the Company in order to give the Supervisory Board an opportunity to express its opinion on such transactions prior to their implementation. 

The Chairman of the Supervisory Board and the Chief Executive Officer as well as other members of the Management Board discussed current and ongoing topics via numerous conference calls, carried out whenever appropriate. 

Details on the Management Board are provided on Evotec’s website under www.evotec.com; section ‘About’.

Supervisory Board (“Aufsichtsrat”)

Following the Articles of Association, the Evotec Supervisory Board consists of six members. The current members of the Evotec Supervisory Board have been (re-)elected at the AGM 2019 with their tenure ending at the end of the AGM 2024. Evotec’s Supervisory Board members were, in accordance with the Code’s recommendations regardless of gender, nationality or age, appointed on the basis of their qualifications, work experience, independence and diversity.

The Supervisory Board has specified concrete objectives and a corresponding competence profile regarding its composition, which are ensured when making proposals to the AGM for election or re-election of new Supervisory Board members. These objectives stipulate that the activities of the Company shall be represented by having a majority of independent Supervisory Board members with national and international experience in the respective fields of (i) Research and Development, (ii) Finance, Capital markets, Legal, Corporate Governance, (iii) Marketing and Sales and Operations and (iv) Healthcare Economy/Public Health. Potential conflict-of-interest situation(s) shall be avoided by deploying the highest scrutiny when assessing potential candidates. In addition, the Supervisory Board shall ensure that the individual age of a candidate shall not exceed 72 years at the time of the proposal. Diversity with regard to female representation shall be ensured by having a target quota of at least 30% female members of the Supervisory Board. Finally, the Supervisory Board has agreed on two full terms as the regular limit of length of membership to the Supervisory Board. Currently, the Chairman of the Supervisory Board, Prof. Dr. Plischke, and the Deputy Chairman of the Supervisory Board, Prof. Dr. Löw-Friedrich, are in their second full term of office, which ends with the 2024 Annual General Meeting. Overall, the Supervisory Board shall be composed in such a way that the majority of its members are independent and that its members as a group possess the knowledge, ability and expert experience required to properly complete its tasks.

Currently, the composition of Evotec’s Supervisory Board fulfils all those objectives: Five members are considered independent within the meaning of the Code, as they have no personal or business relationship with the Company or its Management Board that could constitute a material and not merely temporary conflict of interest. Only Dr Mario Polywka, being Evotec COO until 31 December 2018, who has been elected to the Supervisory Board on the recommendations of a group of shareholders who combined hold more than 25% of the total number of voting rights in the Company, is considered as not independent. Prof Dr Wolfgang Plischke (member of the Supervisory Board of Bayer AG) is independent. Dual membership of the Supervisory Boards of two companies with business relations does not constitute a relationship of dependency, since one member of the Supervisory Board primarily performs control and monitoring functions and is not involved in any operating activities. Prof Dr Iris Löw-Friedrich (Chief Medical Officer and Head of Development & Medical Practices of UCB S.A.) is also independent in the opinion of the Company. Her position on the Executive Board of UCB S.A., which has a business relationship with Evotec SE, does not constitute a dependency. Business relationships are only suitable in exceptional cases to constitute a material and not merely temporary conflict of interest. The Supervisory Board has no influence on the volume of orders, the continuation or expansion of the business relationship; this is the responsibility of the Management Board of Evotec SE, which not only represents the Company (Section 78 of the German Stock Corporation Act (AktG)), but also makes decisions on these matters under its own responsibility (Section 76, paragraph (1) of the German Stock Corporation Act (AktG)). There is also no intersecting executive body position. Dr Michael Shalmi is to be considered an independent member of the Supervisory Board despite his former position on the Management Board of Novo Holding A/S. Novo Holding A/S holds just over 10% of the voting shares in Evotec SE and is therefore not a controlling shareholder. A control leading to independence of the shareholder (and thus also of Dr. Shalmi) would be given if a control agreement with the shareholder exists, the shareholder has an absolute majority of the voting rights or at least a sustainable majority at the Annual General Meeting. A voting interest of just over 10% does not constitute a sustainable majority of the voting rights in favor of Novo Holding A/S and therefore does not constitute a conflict of interest, especially since the number of validly cast votes at past general meetings regularly amounted to well over 40% of the share capital. Dr Elaine Sullivan (former CEO of Carrick Therapeutics Ltd) is also independent. Evotec SE holds approximately 4.3% of the shares in Carrick Therapeutics Ltd. At present, Evotec is not a significant partner of Carrick Therapeutics Ltd. Therefore, there is no conflict of interest that could conflict with independence, for two reasons: (1) Evotec SE's participation rights in Carrick Therapeutics Ltd. are exercised by the Executive Board of Evotec SE on its own responsibility pursuant to Section 76 (1) of the German Stock Corporation Act (AktG); in particular, a member of the Supervisory Board has no influence on voting on the resolutions of the shareholders of Carrick Therapeutics Ltd. Nor are any other significant connections to members of the company's Management Board discernible through their involvement in other companies or organisations. Mr Roland Sackers (CFO of Qiagen N.V.) is independent. Qiagen N.V. has no significant business relationship with Evotec SE; no other circumstances leading to dependency are apparent.

Four different nationalities are represented in the Supervisory Board of the Company and two members are female. The current composition of the Supervisory Board fully represents the competence profile as set out above and lastly confirmed by the Supervisory Board in 2019.

The Supervisory Board advises and oversees the Management Board in the management of the Company. Based upon regular consultations with the Management Board, the Supervisory Board is involved in strategic and planning decisions and all decisions of fundamental importance to the Company. 

Furthermore and upon request, the Supervisory Board Chair is available to discuss Supervisory Board-related issues with investors.

In accordance with the internal rules of procedure, decisions taken by the Management Board on major transactions such as issues, which by corporate law require the Supervisory Board to decide, the strategic and operational direction of the Company, the annual budget, major acquisitions, investment or licence agreements, establishing and acquiring companies or material changes to the Group structure (either by +/- 5% of ownership or to the effect that control in such entity is assumed or lost), business contracts outside the Company’s ordinary course of business that have significantly different risk profiles as well as establishing new business operations or significantly revising existing business operations, require the approval of the Supervisory Board.

The Chairman of the Supervisory Board coordinates the work in the Supervisory Board, calls and chairs its meetings and externally represents the concerns of the body.

The articles of association provide that while resolutions shall typically be passed in meetings, however, upon the Chairman’s instruction resolutions can be passed without a meeting by written notice, by telephone, facsimile, e-mail or by other conventional means of communication. The articles of association further provide that more than half of the members of the Supervisory Board must participate in voting on a resolution to constitute a quorum. If such a quorum is not met a new meeting shall be called with a notice period of two weeks, in which case three present board members constitute a quorum. Absent members may participate in a resolution by delivering a written vote to the Supervisory Board. Unless otherwise required by law or by the articles of association, resolutions of the Supervisory Board are passed by a simple majority of the votes cast. 

The Supervisory Board has its own internal rules of procedure (see www.evotec.com; Invest section) and complies with the Code’s suggestion to hold occasional separate discussions.

The Supervisory Board was not informed about any potential conflict of interest among one of its members in the course of 2019.

The Supervisory Board regularly every two years examines the efficiency and best practice review recommended in the Corporate Governance Code. All Supervisory Board members are questioned by means of a questionnaire, which is evaluated by the Corporate Office. The evaluation and possible recommendations for action are presented to the Supervisory Board for discussion. To date all such audits have led to the conclusion that the Supervisory Board is organised efficiently and that the Management Board and the Supervisory Board interact efficiently and effectively. 

An overview of its work can be found in the following table:

C = Chairman | M = Member

Initial appointment
End of tenure1)
 
Audit Committee
Remuneration and Nomination Committee
Prof. Dr Wolfgang Plischke (Chairman)
2014
2024
C
Prof. Dr Iris Löw-Friedrich (Vice Chairman)
2014
2024
M
Dr Mario Polywka
2019
2024
Roland Sackers
2019
2024
C
M
Michael Shalmi
2017
2024
M
Dr Elaine Sullivan
2015
2024
M
Prof. Dr Wolfgang Plischke (Chairman)
Initial appointment 2014
End of tenure1)
 
2024
Audit Committee
Remuneration and Nomination Committee C
Prof. Dr Iris Löw-Friedrich (Vice Chairman)
Initial appointment 2014
End of tenure1)
 
2024
Audit Committee M
Remuneration and Nomination Committee
Dr Mario Polywka
Initial appointment 2019
End of tenure1)
 
2024
Audit Committee
Remuneration and Nomination Committee
Roland Sackers
Initial appointment 2019
End of tenure1)
 
2024
Audit Committee C
Remuneration and Nomination Committee M
Michael Shalmi
Initial appointment 2017
End of tenure1)
 
2024
Audit Committee
Remuneration and Nomination Committee M
Dr Elaine Sullivan
Initial appointment 2015
End of tenure1)
 
2024
Audit Committee M
Remuneration and Nomination Committee

1) Following the AGM in June 2024

Information on the professional affiliations of board members and on related party transactions can be found in the Annual Report of the Company. In addition, details on the Supervisory Board are provided on Evotec’s website under www.evotec.com; section ‘About’.

Work in Supervisory Board Committees

A significant proportion of the Supervisory Board’s work is conducted in committees. From among its members, Evotec’s Supervisory Board has established, pursuant to the German Stock Corporation Act and the recommendations of the Code, an Audit Committee as well as a Remuneration and Nomination Committee. Members of both committees are appointed in accordance with the Code.

For information about the composition of the Supervisory Board Committees please see the website of the Company under www.evotec.com in the Invest section.

Evotec’s Audit Committee, comprising three members, supports the Supervisory Board in independently monitoring the Company’s financial reporting activities and in auditing reports. In particular, the Audit Committee scrutinises the Company’s accounting processes, the effectiveness of the internal control system and the audit. In addition, it discusses the quarterly and half-year reports with the members of the Management Board. Within the scope of the audit of the financial statements commissioned by the Supervisory Board, the Audit Committee also discusses certain steps and procedures of the audit with the appointed auditing firm, including the auditors’ independence, the additional services rendered by the auditor, the issuing of the audit mandate to the auditing firm, the determination of auditing focal points, the fee agreement and compliance issues.

The members of the Audit Committee possess the required skills and experience. As a Chief Financial Officer, the Audit Committee’s Chairman Roland Sackers, who succeeded Bernd Hirsch in June 2019, is not only independent, but also has the required specialist knowledge and experience in the application of accounting principles and internal control processes. Neither the Chairman of the Supervisory Board nor a former member of the Management Board may become Chairman of the Audit Committee. Evotec’s Audit Committee Charter can be found on the Company’s website (www.evotec.com) in the Invest section.

The committee meets at least four times annually. The audit committee shall have a quorum if at least two of its members participate in the passing of a resolution. Resolutions require a simple majority of the votes cast. Evotec’s Audit Committee Charter can be found on the Company’s website (www.evotec.com) in the Invest section.

The main duties and responsibilities of the Company’s Remuneration and Nomination Committee are to prepare the appointment of Management Board members and to prepare recommendations concerning their remuneration system and Share Performance Plan. Final decisions are made by the full Supervisory Board.

Remuneration of Board members

Evotec complies with the recommendations of the Corporate Governance Code to provide details of the remuneration of each individual member of the Management Board and the Supervisory Board. Detailed information on the remuneration of Management Board members, divided into fixed and variable compensation components as well as any fringe benefits, and remuneration of Supervisory Board members is reported in a separate section of the Management Report (“Remuneration Report”) of the Evotec Annual Report. The Evotec Annual Report is available on the website of the Company under www.evotec.com in the Invest section. The remuneration of the Board Members is also publicised on Evotec’s website under www.evotec.com/en/invest/corporate-governance in the Invest section.

In accordance with good corporate practice, the Supervisory Board of Evotec SE proposed the system of remunerating members of the Management Board for approval to the AGMs in 2017 and again in 2019 (“say on pay”). At both AGMs, the majority of the shareholders and shareholder representatives voted in favour of this agenda item, in 2019 with 89% of the present votes.

Evotec procured directors and officer’s liability insurance cover for its Management and Supervisory Board members, its senior management and the directors of its subsidiaries at a cost to the Company. For the members of Supervisory Board, an appropriately sized deductible, and for the members of the Management Board, a deductible in line with the stipulations of the legal provisions of the VorstAG, were agreed upon.

Shareholders and Annual General Meeting (AGM)

Evotec SE shareholders exercise their co-determination and monitoring rights at the AGM, convened at least once a year. The AGM takes decisions on all statutory matters that are binding on all shareholders and the Company. For voting on resolutions, each share confers one vote.

All shareholders registering in due time are entitled to participate in the AGM. Evotec offers shareholders who are unable to attend the AGM the opportunity to access key parts of the event live on the internet. The Company also encourages non-attendees to exercise their voting rights by arranging independent proxies who are bound to the shareholders’ instructions. Shareholders may also authorise a person of their choice to represent them at the meeting. 

The invitation to the AGM and the reports and information required for voting are published in accordance with the provisions of the German Stock Corporation Act and provided in German and English on Evotec’s website under www.evotec.com in the Invest section.

Directors’ Dealings

Under the European Market Abuse Regulation, the members of the Supervisory Board and the Management Team of Evotec as well as persons who have a close relationship with these persons are obligated to report trading in Evotec stock so far as the transactions exceed in aggregate € 5,000.00 (the de minimus threshold) per calendar year. In addition, Evotec has established an Insider Trading Policy (see www.evotec.com; Invest section) that sets standards for board members’ and employees’ trading in Evotec shares and thus ensures transparency. 

During 2019, the following Directors’ Dealings were reported:

Date
Name
Position
Type
No of items
Price
Total
15 Nov 2019
Werner Lanthaler
Member of Management
Purchase
10,000
€ 18.4725
€ 184,724.80
24 Sep 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
13,950
€ 20.4628
€ 285,456.06
24 Sep 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
54,263
€ 20.4628
€ 1,110,372.9164
24 Sep 2019
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
71,873
€ 20.3379
€ 1,461,745.8867
24 Sep 2019
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
109,863
€ 20.3379
€ 2,234,382.7077
24 Sep 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
57,167
€ 20.4628
€ 1,169,796.8876
23 Sep 2019
Cord Dohrmann
Member of Management
Purchase of shares by exercising stock options (Share Performance Plan)
26,900
€ 20.3379
€ 547,089.51
 
20 Sep 2019
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
27,078
€ 20.0086 
€ 541,792.8708
20 Sep 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
14,050
€ 20.0086 
€ 281,120.83
03 Sep 2019
Werner Lanthaler
Member of Management
Purchase
10,000
€ 19.00
€ 190,000.00
19 Aug 2019
Werner Lanthaler
Member of Management
Purchase
10,000
€ 18.866059
€ 188,660.59
15 Aug 2019
Cord Dohrmann
Member of Management
Purchase
1,000
€ 19.0375
€ 19,037.50
12 Jul 2019
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Share Performance Plan)
280
€ 24.40
€ 6,832.00
12 Jul 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
290
€ 24.40
€ 7,076.00
04 Jul 2019
Craig Johnstone
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
7,126
€ 23.9312
€ 170,533.7312
 
03 Jul 2019
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Share Performance Plan)
55,000
€ 24.50
€ 1,347,500.00
03 Jul 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
84,630
€ 24.50
€ 2,073,435.00
31 May 2019
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
50,000
€ 19.4458
€ 972,290.00
29 May 2019
Craig Johnstone
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
7,000
€ 21.6392
€ 151,474.40
12 Feb 2019
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Share Performance Plan)
30,000
€ 19.5429
€ 586,287.00
12 Feb 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
70,000
€ 19.5429
€ 1,368,003.00
11 Feb 2019
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Share Performance Plan)
30,000
€ 19.2454
€ 577,362.00
 
11 Feb 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
70,000
€ 19.2454
€ 1,347,178.00
22 Jan 2019
Cord Dohrmann
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
50,000
€ 19.3282
€ 966,410.00
11 Jan 2019
Werner Lanthaler
Member of Management
Purchase of shares by exercising stock options (Share Performance Plan)
80,190
€ 19.0599
€ 1,528,413.38
11 Jan 2019
Werner Lanthaler
Member of Management
Exercise against Cash Settlement (Share Performance Plan)
69,810
€ 19.0599
€ 1,330,571.62
Date 15 Nov 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase
No of items 10,000
Price € 18.4725
Total € 184,724.80
Date 24 Sep 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 13,950
Price € 20.4628
Total € 285,456.06
Date 24 Sep 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 54,263
Price € 20.4628
Total € 1,110,372.9164
Date 24 Sep 2019
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 71,873
Price € 20.3379
Total € 1,461,745.8867
Date 24 Sep 2019
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 109,863
Price € 20.3379
Total € 2,234,382.7077
Date 24 Sep 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 57,167
Price € 20.4628
Total € 1,169,796.8876
Date 23 Sep 2019
Name Cord Dohrmann
Position Member of Management
Type Purchase of shares by exercising stock options (Share Performance Plan)
No of items 26,900
Price € 20.3379
Total € 547,089.51
 
Date 20 Sep 2019
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 27,078
Price € 20.0086 
Total € 541,792.8708
Date 20 Sep 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 14,050
Price € 20.0086 
Total € 281,120.83
Date 03 Sep 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase
No of items 10,000
Price € 19.00
Total € 190,000.00
Date 19 Aug 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase
No of items 10,000
Price € 18.866059
Total € 188,660.59
Date 15 Aug 2019
Name Cord Dohrmann
Position Member of Management
Type Purchase
No of items 1,000
Price € 19.0375
Total € 19,037.50
Date 12 Jul 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Share Performance Plan)
No of items 280
Price € 24.40
Total € 6,832.00
Date 12 Jul 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 290
Price € 24.40
Total € 7,076.00
Date 04 Jul 2019
Name Craig Johnstone
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 7,126
Price € 23.9312
Total € 170,533.7312
 
Date 03 Jul 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Share Performance Plan)
No of items 55,000
Price € 24.50
Total € 1,347,500.00
Date 03 Jul 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 84,630
Price € 24.50
Total € 2,073,435.00
Date 31 May 2019
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 50,000
Price € 19.4458
Total € 972,290.00
Date 29 May 2019
Name Craig Johnstone
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 7,000
Price € 21.6392
Total € 151,474.40
Date 12 Feb 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Share Performance Plan)
No of items 30,000
Price € 19.5429
Total € 586,287.00
Date 12 Feb 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 70,000
Price € 19.5429
Total € 1,368,003.00
Date 11 Feb 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Share Performance Plan)
No of items 30,000
Price € 19.2454
Total € 577,362.00
 
Date 11 Feb 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 70,000
Price € 19.2454
Total € 1,347,178.00
Date 22 Jan 2019
Name Cord Dohrmann
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 50,000
Price € 19.3282
Total € 966,410.00
Date 11 Jan 2019
Name Werner Lanthaler
Position Member of Management
Type Purchase of shares by exercising stock options (Share Performance Plan)
No of items 80,190
Price € 19.0599
Total € 1,528,413.38
Date 11 Jan 2019
Name Werner Lanthaler
Position Member of Management
Type Exercise against Cash Settlement (Share Performance Plan)
No of items 69,810
Price € 19.0599
Total € 1,330,571.62

Directors’ Shareholdings

As of 31 December 2019, the members of the Management Board and the Supervisory Board owned the following shares in the Company:

Shares
Stock options
Outstanding shares from vested Share Performance Awards
Granted unvested Share Performance Awards (total)
Management Board
Dr Werner Lanthaler
1,111,736
 
-
245,084
421,594
Enno Spillner
-
-
103,356
Dr Cord Dohrmann
145,991
32,594
 
111,215
124,327
Dr Craig Johnstone
-
-
21,086
40,980
Supervisory Board
Prof. Dr Wolfgang Plischke
-
-
-
-
Prof. Dr Iris Löw-Friedrich 
-
-
-
-
Dr Mario Polywka
-
-
127,155
107,409
Roland Sackers
-
-
-
-
Michael Shalmi
-
-
-
-
Dr. Elaine Sullivan
-
-
-
-
Management Board  
Shares
Stock options
Outstanding shares from vested Share Performance Awards
Granted unvested Share Performance Awards (total)
Dr Werner Lanthaler  
Shares
1,111,736
 
Stock options -
Outstanding shares from vested Share Performance Awards 245,084
Granted unvested Share Performance Awards (total) 421,594
Enno Spillner  
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards
Granted unvested Share Performance Awards (total) 103,356
Dr Cord Dohrmann  
Shares 145,991
Stock options
32,594
 
Outstanding shares from vested Share Performance Awards 111,215
Granted unvested Share Performance Awards (total) 124,327
Dr Craig Johnstone  
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards 21,086
Granted unvested Share Performance Awards (total) 40,980
 
Shares
Stock options
Outstanding shares from vested Share Performance Awards
Granted unvested Share Performance Awards (total)
Supervisory Board  
Shares
Stock options
Outstanding shares from vested Share Performance Awards
Granted unvested Share Performance Awards (total)
Prof. Dr Wolfgang Plischke  
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards -
Granted unvested Share Performance Awards (total) -
Prof. Dr Iris Löw-Friedrich   
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards -
Granted unvested Share Performance Awards (total) -
Dr Mario Polywka  
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards 127,155
Granted unvested Share Performance Awards (total) 107,409
Roland Sackers  
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards -
Granted unvested Share Performance Awards (total) -
Michael Shalmi  
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards -
Granted unvested Share Performance Awards (total) -
Dr. Elaine Sullivan  
Shares -
Stock options -
Outstanding shares from vested Share Performance Awards -
Granted unvested Share Performance Awards (total) -

Changes to the directors’ shareholdings will be published on Evotec website under www.evotec.com in the Invest section.

Directors' Dealings

Notification about Directors’ Dealings under article 19 European Market Abuse Regulation (MAR)

  • Information about the transaction with duty of notification
  • Description of the financial instrument: Share
  • ISIN of the financial instrument: DE0005664809
 

Directors' Shareholdings

as of 31 December 2019

Shares
Stock options
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Management Board
Dr Werner Lanthaler
1,111,736
-
245,084 
421,594 
Enno Spillner
-
-
-
103,356
Dr Cord Dohrmann
145,991
32,594
111,215
124,327
Dr Craig Johnstone
-
-
21,086
40,980
Supervisory Board
Prof. Dr Wolfgang Plischke
-
-
-
-
Prof. Dr Iris Löw-Friedrich
-
-
-
-
Dr Mario Polywka
-
-
127,155
107,409
Roland Sackers
-
-
-
-
Dr Michael Shalmi
-
-
-
-
Dr Elaine Sullivan
-
-
-
-
Management Board  
Shares
Stock options
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Dr Werner Lanthaler  
Shares 1,111,736
Stock options -
Outstanding Shares from vested SPA's 245,084 
Granted unvested SPA's (total) 421,594 
Enno Spillner  
Shares -
Stock options -
Outstanding Shares from vested SPA's -
Granted unvested SPA's (total) 103,356
Dr Cord Dohrmann  
Shares 145,991
Stock options 32,594
Outstanding Shares from vested SPA's 111,215
Granted unvested SPA's (total) 124,327
Dr Craig Johnstone  
Shares -
Stock options -
Outstanding Shares from vested SPA's 21,086
Granted unvested SPA's (total) 40,980
 
Shares
Stock options
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Supervisory Board  
Shares
Stock options
Outstanding Shares from vested SPA's
Granted unvested SPA's (total)
Prof. Dr Wolfgang Plischke  
Shares -
Stock options -
Outstanding Shares from vested SPA's -
Granted unvested SPA's (total) -
Prof. Dr Iris Löw-Friedrich  
Shares -
Stock options -
Outstanding Shares from vested SPA's -
Granted unvested SPA's (total) -
Dr Mario Polywka  
Shares -
Stock options -
Outstanding Shares from vested SPA's 127,155
Granted unvested SPA's (total) 107,409
Roland Sackers  
Shares -
Stock options -
Outstanding Shares from vested SPA's -
Granted unvested SPA's (total) -
Dr Michael Shalmi  
Shares -
Stock options -
Outstanding Shares from vested SPA's -
Granted unvested SPA's (total) -
Dr Elaine Sullivan  
Shares -
Stock options -
Outstanding Shares from vested SPA's -
Granted unvested SPA's (total) -

For a detailed description of the stock option plans and Share Performance Awards for the directors and employees of Evotec Group, please refer to the latest financial reports.

Supervisory Board committees

C = Chairman

M = Member

Initial appointment
End of tenure1)
Audit Committee
Remuneration and Nomination Committee
Prof. Dr Wolfgang Plischke (Chairman)
2014
2024
C
Prof. Dr Iris Löw-Friedrich (Vice Chairperson)
2014
2024
M
Dr Mario Polywka
2019
2024
Roland Sackers
2019
2024
C
M
Dr Michael Shalmi
2017
2024
M
Dr Elaine Sullivan
2015
2024
M
Prof. Dr Wolfgang Plischke (Chairman)  
Initial appointment 2014
End of tenure1) 2024
Audit Committee
Remuneration and Nomination Committee C
Prof. Dr Iris Löw-Friedrich (Vice Chairperson)  
Initial appointment 2014
End of tenure1) 2024
Audit Committee M
Remuneration and Nomination Committee
Dr Mario Polywka  
Initial appointment 2019
End of tenure1) 2024
Audit Committee
Remuneration and Nomination Committee
Roland Sackers  
Initial appointment 2019
End of tenure1) 2024
Audit Committee C
Remuneration and Nomination Committee M
Dr Michael Shalmi  
Initial appointment 2017
End of tenure1) 2024
Audit Committee
Remuneration and Nomination Committee M
Dr Elaine Sullivan  
Initial appointment 2015
End of tenure1) 2024
Audit Committee M
Remuneration and Nomination Committee

1) Following the AGM in June 2024

 

Supervisory Board member
Number of Supervisory Board and committee meetings
Participation
Presence*
Prof. Dr Wolfgang Plischke (Chairman)
6+4
6+4
100%
Prof. Dr Iris Löw-Friedrich (Vice Chairperson)
6+4
5+3
80%
Dr Mario Polywka1
3+0
2+0
67%
Roland Sackers1
3+4
2+4
86%
Michael Shalmi
6+4
5+4
90%
Dr Elaine Sullivan
6+4
5+3
80%
Bernd Hirsch (Vice Chairman)2
3+4
3+4
100%
Dr Claus Braestrup2
3+2
3+2
100%
Supervisory Board member Prof. Dr Wolfgang Plischke (Chairman)
Number of Supervisory Board and committee meetings 6+4
Participation 6+4
Presence* 100%
Supervisory Board member Prof. Dr Iris Löw-Friedrich (Vice Chairperson)
Number of Supervisory Board and committee meetings 6+4
Participation 5+3
Presence* 80%
Supervisory Board member Dr Mario Polywka1
Number of Supervisory Board and committee meetings 3+0
Participation 2+0
Presence* 67%
Supervisory Board member Roland Sackers1
Number of Supervisory Board and committee meetings 3+4
Participation 2+4
Presence* 86%
Supervisory Board member Michael Shalmi
Number of Supervisory Board and committee meetings 6+4
Participation 5+4
Presence* 90%
Supervisory Board member Dr Elaine Sullivan
Number of Supervisory Board and committee meetings 6+4
Participation 5+3
Presence* 80%
Supervisory Board member Bernd Hirsch (Vice Chairman)2
Number of Supervisory Board and committee meetings 3+4
Participation 3+4
Presence* 100%
Supervisory Board member Dr Claus Braestrup2
Number of Supervisory Board and committee meetings 3+2
Participation 3+2
Presence* 100%

* Commercially rounded
1 In the Supervisory Board since AGM in June 2019
2 In the Supervisory Board until AGM in June 2019

Remuneration report

The remuneration report describes the Company’s remuneration system and provides information about payments to the board members in accordance with the requirements of the German Corporate Governance Code (the “Code”). It is part of both the Consolidated Financial Statements and the Corporate Governance report.

Remuneration of the Management Board

The remuneration system of the Management Board is fixed by the Supervisory Board and is composed of performance-unrelated and performance-related components. 

As a principle, Management Board compensation is awarded based on an assessment of performance that is oriented towards the sustainable growth of Evotec. The criteria for determining the amount of compensation awarded include the tasks of the individual members of the Management Board, their personal performance, the economic situation of the Company, the performance and outlook of Evotec as well as the comparative level of compensation at peer companies and the compensation structure in place in other areas of the Company. Moreover, the Supervisory Board considers the Management Board compensation relative to that of senior management as well as the staff overall, particularly in terms of its development over time. 

Following the Code, the remuneration system specifies a target compensation and monetary caps for both the total compensation and the respective compensation components for each Board member. Deviating from that, the Share Performance Plans 2012 and 2015 as approved by the AGMs in 2012 and 2015 include a maximum regarding the number of share-based awards (Share Performance Awards, “SPA”) upon allocation. The monetary value of the allocated shares is determined by the share price after the expiration of the vesting period. The Share Performance Plan 2017 has a monetary cap for the Management Board with a maximum level of 350% of the contractual SPA issue value and therefore complies with the Code in all respects.

Benchmarking against other national and international biotech companies and members of the TecDAX and MDAX index as well as a comparison with Corporate Governance best practices is conducted on a periodic basis and prior to each renewal of the management contracts with the support of renowned external compensation and benefits experts. This benchmarking includes monetary aspects and current corporate governance best practices. Based on this benchmarking exercise, the Supervisory Board considers the current remuneration system and its fixed and variable compensation levels with regard to the duties and responsibilities of the Management Board members and decides on adjustments of the management contracts. As an example of the consequence of this practice, a clawback clause has been added to those Management contracts which have been recently renewed.

In accordance with good corporate practice, the Supervisory Board of Evotec SE proposed the system of remunerating members of the Management Board for approval to the AGMs in 2017 and again in 2019 (“say on pay”). At both AGMs, the majority of the shareholders and shareholder representatives voted in favour of this agenda item.

Performance-unrelated remuneration

Performance-unrelated remuneration includes base salaries as fixed compensation paid in twelve monthly instalments at the end of each month and fringe benefits such as pension allowances, contribution to commuting expenses, contributions to certain premiums for insurance policies as well as the benefit derived from the private use of a company car or a car allowance. In addition to the aforementioned remuneration, businessrelated private payments, expenditures and expenses are reimbursed.

Performance-related remuneration

The performance-related remuneration components consist of a one-year variable compensation (Short Term Incentive or “STI”) determined by a bonus scheme and a long-term Share Performance Plan, which was approved by the AGMs 2012, 2015 and 2017. The one-year variable remuneration is determined by a bonus scheme based on the achievement of certain targets specified by the Remuneration and Nomination Committee of the Supervisory Board and subsequently approved by the Supervisory Board for each financial year. The Share Performance Plans are based on a forwardlooking, multi-year assessment period.

The STI bonus scheme for the Management Board is based on the achievement of clearly measurable corporate objectives equally set for each Management member by the Supervisory Board rather than individual objectives. Such corporate objectives are geared to support the mid- and long-term growth strategy of the Company and generally relate to financial objectives, such as growth in total revenues, adjusted EBITDA and R&D expenses as set in accordance with the relevant guidance for that specific financial year, plus operational, strategic and cultural objectives. In its March meeting, the Supervisory Board reviews the achievement of these corporate objectives of the previous year and approves the respective bonus pay-out.

The target bonuses for the one-year variable compensation amount to 100% of the fixed remuneration for the Chief Executive Officer (2018: 100%) and to 70% of the fixed remuneration for all other members of the Management Board (2018: 75% for the Chief Operating Officer, 70% for the Chief Scientific Officer and 55% for the Chief Financial Officer).

In addition to the one-year variable compensation, the members of the Management Board are eligible for an annual grant of Share Performance Awards (SPAs) under Evotec’s current Share Performance Plan 2017, building the basis for the Long Term Incentive or “LTI”. The Evotec Share Performance Plan is an important step in supporting the interests of the Company’s shareholders and in establishing a state-of-the-art long-term compensation that is in line with remuneration and corporate governance standards as well as the German Corporate Governance Code. 

The number of granted SPAs is determined by dividing a defined percentage of the Board member’s total direct compensation (base salary, target annual bonus (STI) and target long-term incentives (LTI)) by the applicable fair market value of an SPA. The percentage amounts to 50% of total direct compensation for the Chief Executive Officer (2018: 50%) and to 35% of total direct compensation for all other members of the Management Board (2018: 30%).

For each annual award of SPAs, a Performance Measurement Period of four consecutive calendar years applies. Two equally weighted external Key Performance Indicators (KPIs) have been set forth by the Annual General Meeting 2017 oriented on long-term value creation, consisting of “Share Price” and “Relative Total Shareholder Return” (yield on shares). Relative Total Shareholder Return is a measure to determine the performance of an investment in the shares of the Company compared to the TecDAX. Relative Total Shareholder Return measures the return on a share investment over a period of time, including dividends as well as share price performance (positive and negative) and adjusted for any equity issues or share-splits. The KPIs are measured for each year of the Performance Measurement Period. The achieved performance for a respective year is locked-in for the remaining Vesting Period.

Within each of the two KPIs there is a “Minimum Target” that has to be reached for Share Performance Awards to be exercised (partially), as well as a “Maximum Target” that, once it is reached, allows for all Share Performance Awards for the respective KPI (100%) to be exercised to the full amount, after the Vesting Period has expired (one Share Performance Award entitles the holder to subscribe in the maximum for no more than two whole shares in Evotec SE). 

100% of the KPI “Share Price” (the “Target Share Price”) is achieved for a calendar year if the average share price of the Company stock in the closing auction of XETRA trading (or a corresponding successor system) on the last 30 trading days of the Frankfurt stock exchange in the respective performance period, i.e. a calendar year (the “Closing Price”) exceeds by 8% the average share price of the Company stock in the closing auction of XETRA trading (or a corresponding successor system) on the last 30 trading days of the Frankfurt stock exchange before the start of the respective performance period (the “Opening Price”). The Minimum Target for the KPI “Share Price” is reached if the Closing Price is higher than the Opening Price. The Maximum Target for the KPI “Share Price”, which entitles all Share Performance Awards for this KPI to be exercised for the respective performance period, is reached if the Closing Price is 16% or more above the Opening Price.

100% of the KPI “Relative Total Shareholder Return” is achieved for a calendar year (the “Target Relative Total Shareholder Return”), when the Total Shareholder Return for the shares of the Company (average share

price of the Company at the closing auction of XETRA trading on the 30 trading days at Frankfurt Stock exchange prior to the relevant date plus dividends, and adjusted for any equity issuance or share-splits, matches the Total Shareholder Return of the German TecDAX index during the same period. The Minimum Target for the KPI “Relative Total Shareholder Return” is achieved when the annual average Total Shareholder Return for the shares of the Company is 10 percentage points below the Total Shareholder Return of the TecDAX during the respective performance period (i.e. each calendar year). The Maximum Target, at which all the Share Performance Awards for the KPI “Relative Total Shareholder Return” can be exercised, is achieved when the annual average Total Shareholder Return for the shares of the Company is at least 10 percentage points above the average Total Shareholder Return of the TecDAX during the respective performance period. Relevant values of the Total Shareholder Return of the Company and of the Total Shareholder Return of the TecDAX will be calculated annually and based on the average TecDAX (Total Return Index) during the 30 trading days at Frankfurt Stock exchange prior to the relevant date.

The right to exercise awards from the Share Performance Plan arises only on expiry of the Vesting Period after four years of the respective SPA tranche. Depending on the achievement of the Key Performance Indicators (KPIs) for each of the four years, each Share Performance Award entitles the participant to the subscription of up to a maximum of two Company shares (200% cap). After each of the four performance periods (i.e. each calendar year) for a tranche of Share Performance Awards has ended, the target achievement for the two KPIs is determined for the respective calendar year and the corresponding number of subscription rights are calculated and provisionally set. At the end of all the four performance periods, i.e. the four calendar years of one tranche, the subscription rights determined for each year are added and represent the total number of exercisable subscription rights.

Each participant is required to make a payment of the nominal amount of € 1 (one Euro) per share to Evotec upon exercising, independent from the trading price of the Evotec share at that point in time. The new shares received are not subject to any specific lock-up; they are freely tradable immediately subject to insider trading rules which are the sole responsibility of each participant.

The Supervisory Board reserves the right at its sole discretion to replace the shares to be allocated to the participants with a cash payment and/or Evotec shares kept in treasury by the Company. The value of the shares to be used in calculating the cash payment shall be the average share price during the 30 day trading period immediately before the Vesting date.

Remuneration Report of the Management Board

The Management Board compensation for 2019 was carried out in full compliance with the Company’s remuneration system as approved by the Annual General Meeting (AGM) and the monetary cap for both the total compensation and the respective compensation components.

The 2019 corporate objectives related to financial objectives, such as growth in total revenues, adjusted EBITDA and R&D expenses as set in accordance with the relevant guidance for that specific financial year 2019. Further targets included the execution of at least two significant asset transactions in EVT Innovate and at least one new alliance more than € 20 m in transaction value, the building at least two new academic BRIDGEs and preparing the Company for sustainable growth. The individual Corporate Objectives for 2019 are set out in the following table:

 

The bonus for the achievement of the targets set for the financial year 2019 will be paid out to the Management Board members in March 2020. Based on the 100% achievement of the Corporate Objectives 2019 this will be total of T€ 1,222 for the variable portion of the remuneration to be paid to the members of the Management Board.

In addition to their one-year variable compensation, the members of the Management Board received a total of 86,283 SPAs in January 2019 (2018: 103,861) under the Company’s Share Performance Plan, thereof 45,161 SPAs for Dr Werner Lanthaler, 13,318 SPAs for Dr Cord Dohrmann, 16,733 SPAs for Dr Craig Johnstone and 11,071 SPAs for Enno Spillner. The fair value of all SPAs granted as multi-year variable compensation amounted to T€ 1,605 (2018: T€ 1,529) on the day of calculation on 1 January 2019. The reduced amount of SPAs in 2019 compared to 2018 is due to the increased share price in 2019 and the resulting increase in fair market value recognised per SPA. The SPAs that were granted in January 2019 vest and become exercisable after four years in January 2023.

Remuneration tables

For 2019, the performance-unrelated and one-year variable compensation of the active members of the Management Board totalled T€ 2,607, of which the variable part amounted to T€ 903. 

The following tables present for each Management Board member:

  • The benefits granted for the year under review including fringe benefits (such as car allowance, contributions made towards health insurance, a pension, accident/life insurance and accommodation costs) and including the maximum and minimum achievable compensation for variable compensation components
  • The allocation of fixed compensation, fringe benefits, short-term variable compensation and long-term variable compensation for the year under review, broken down into the relevant reference years

 

Term of contract and early termination clauses

In accordance with the Code, new members of the Management Board are appointed for three years. Prolongations of existing contracts might be up to five years as has been agreed with the Chief Executive Officer for his current contract and with the Chief Scientific Officer for his current contract as renewed in 2019.

Their contracts contain a change-of-control clause, which allows them to terminate their current contracts in the event of a change of control. Should members of the Management Board make use of their right to terminate their contracts in the event of a change of control, they are entitled to severance payments determined as follows: for Dr Werner Lanthaler, the severance payment shall be equal to 24 months of his base salary; and for Dr Cord Dohrmann, Dr Craig Johnstone and Enno Spillner, the payment shall be equal to 18 months of their base salary plus target bonuses for this time period. In no case shall the respective severance payment be higher than the total compensation due for the remaining term of the respective Management Board member’s contract.

In accordance with the Code, in case of an early termination of their respective service agreement in the absence of a change-of-control situation, payments to the members of the Management Board shall not exceed the amount of two annual remunerations and shall not exceed the amount of remuneration that would be due until the expiration date of the service agreement.

Remuneration paid to Management Board for other board mandates

Members of the Management Board do not receive any remuneration for intra-group director or board roles. If Supervisory Board mandates are assumed at non-group entities, the Supervisory Board decided that such remuneration received for non-group supervisory board or board of director mandates shall not be offset from the management remuneration.

Pension provisions for Former Management Board members

The Company has made a provision for a pension for one former Management Board member amounting to T€ 205 (2018: T€ 189). No such further provisions are due for other former Management Board members or their surviving dependants.

Remuneration of the Supervisory Board

The remuneration of the members of the Supervisory Board is prescribed in the Company’s Articles of Association.

According to section 113 AktG, Supervisory Board remuneration is to be appropriate to the task of the Supervisory Board members and the situation of the Company. The personal requirements of Supervisory Board members, especially of the Chairman of the Supervisory Board, regarding qualification and the amount of time have increased significantly in recent years. Evotec expects this trend to continue in the future, which is accompanied by an increasing risk exposure and higher liability risks of Supervisory Board members. In order to be well-positioned for attracting top-class Supervisory Board candidates within a competitive international environment, who meet Evotec’s competence profile, the AGM 2019 has approved an increase of the compensation of Supervisory Board members from fiscal year 2019 onwards.

The members of Evotec’s Supervisory Board are entitled to fixed payments as well as out-of-pocket expenses. In accordance with the recommendations of the Code, the Chairman and the Vice Chairman positions on the Supervisory Board as well as the Chair positions and memberships in committees are considered when determining the remuneration of individual members. Consequently, as amended following the approval of the AGM 2019, the fixed compensation is T€ 50 per Supervisory Board member. The Chairman of the Supervisory Board is paid T€ 125, and the Vice Chairman is paid T€ 60. Supervisory Board members serving on its committees shall be paid T€ 10 per committee membership; the Chairman of a committee shall be paid T€ 25.

For their contributions in 2019, the individual members of the Evotec Supervisory Board received the following compensation in 2019:

 

Remuneration of the Supervisory Board 2019

Total remuneration in T€1)
Prof. Dr Wolfgang Plischke
150
Bernd Hirsch*
44
Dr Claus Braestrup*
28
Prof. Dr Iris Löw-Friedrich
65
Dr Mario Polywka**
27
Roland Sackers**
46
Michael Shalmi
60
Dr Elaine Sullivan
60
Total
480
Prof. Dr Wolfgang Plischke
Total remuneration in T€1) 150
Bernd Hirsch*
Total remuneration in T€1) 44
Dr Claus Braestrup*
Total remuneration in T€1) 28
Prof. Dr Iris Löw-Friedrich
Total remuneration in T€1) 65
Dr Mario Polywka**
Total remuneration in T€1) 27
Roland Sackers**
Total remuneration in T€1) 46
Michael Shalmi
Total remuneration in T€1) 60
Dr Elaine Sullivan
Total remuneration in T€1) 60
Total
Total remuneration in T€1) 480

 1) Cash remuneration
Tenure end at AGM 2019
** Tenure starts at AGM 2019

There are currently no consultancy agreements in place between Evotec and current or former members of the Supervisory Board.

Directors’ and Officers’ Liability Insurance (D&O Insurance)

In 2019, Evotec procured directors’ and officers’ liability insurance cover for its Management and Supervisory Board members, its senior management and the directors of its subsidiaries at a cost to the Company of T€ 132 (2018: T€ 82). An appropriately sized deductible was agreed upon for the members of the Supervisory Board. The deductible agreed upon for the members of the Management Board is in line with the stipulations of the legal provisions of the VorstAG.

Share Performance Plan

To incentivise executives via variable long-term incentive compensation, the 2012, 2015 and 2017 Annual General Meetings approved the contingent capital necessary to support the so-called Share Performance Plans (SPP 2012, SPP 2015 and SPP 2017). SPP 2017 is replacing SPP 2012 and SPP 2015. However, this does not affect subscription rights issued before 14 June 2017.

The concrete design of the Share Performance Plans 2012, 2015 and 2017 lean on the concept of a share performance programme. They are characterised by the fact that participating executives are entitled to a variable remuneration in shares, when attaining a demanding target. In contrast to a common stock option programme, when attaining a target, shares are not issued in an amount that at least corresponds to the market rate of the company stock at the time of granting the subscription rights, but at the respectively lowest issue amount of currently € 1.00. The essential reason for this lies in the fact that in a Share Performance Programme, the value of the respective stock takes the place of cash compensation, so that stocks ideally should be issued without counter performance. A special economic advantage, compared to a common stock option programme, does not result for the participants as at the time the subscription rights are granted, and therefore at the outset, it is taken into consideration that the participants receive the total value of the shares (minus the respectively lowest issue amount of currently € 1.00), and not only, as in regular stock option plans, the difference between the market rate when granting subscription rights and the market rate at issue of the shares. The determination of an issue amount of currently € 1.00 is imperative from a corporate law perspective, as the issue of new shares under the respective pro-rata amount of the share capital is not permitted.

Under these plans, Share Performance Awards may be granted to a level that may result in in a total of up to 13,000,000 (4,000,000 for SPP 2012, 3,000,000 for SPP 2015 and 6,000,000 for SPP 2017) bearer shares of the Company being issued at maturity to members of the Management Board and other key employees. During the fourth quarter of 2016, a total of 793,903 SPAs (2015: 796,617 awards) were granted to the Management Board and key employees. These awards could result in a maximum of 1,587,806 bearer shares (2015: 1,593,234) being issued at maturity. This is because each Share Performance Award grants up to two subscription rights to Company shares, each of which in turn entitle the holder to the subscription of one Company share. Previous awards can be found the respective annual financial reports. The holder has to contribute € 1.00 per share at the date of issue. Share Performance Awards can only be exercised, if, when and to the extent that key performance indicators are achieved. Key performance indicators of SPP 2012 and 2015 are “Group Revenues”, “Operating Income Before Impairments”, “Net Cash Generated by Operating Activities” and “Share Price” upon which the Supervisory Board had to determine at least two per grant and define their weighting. SPP 2015 also includes the key performance indicator of “Total Shareholder Return”. Equally weighted key performance indicators of SPP 2017 are only “Share Price” and “Total Shareholder Return”.

Key parameters of the Company’s Share Performance Plan 2017 are depicted in the graphic below.

Detailed information on the Company’s current SPP 2017 as well as previous Share Performance Plans 2012 and 2015 can be found below.

Expiration of stock option schemes

SPP 2012, SPP 2015 and SPP 2017 were implemented to replace the stock option programme as the Company’s long-term incentive compensation scheme for executives. Stock options issued in existing stock option schemes I to VII remain valid.

Date of the Ordinary Annual General Meeting
Programme
07 June 1999
Programme I
26 June 2000
Programme II
18 June 2001
Programme III
07 June 2005
Programme IV
30 May 2007
Programme V
28 August 2008
Programme VI
16 June 2011
Programme VII
Date of the Ordinary Annual General Meeting 07 June 1999
Programme Programme I
Date of the Ordinary Annual General Meeting 26 June 2000
Programme Programme II
Date of the Ordinary Annual General Meeting 18 June 2001
Programme Programme III
Date of the Ordinary Annual General Meeting 07 June 2005
Programme Programme IV
Date of the Ordinary Annual General Meeting 30 May 2007
Programme Programme V
Date of the Ordinary Annual General Meeting 28 August 2008
Programme Programme VI
Date of the Ordinary Annual General Meeting 16 June 2011
Programme Programme VII

Detailed information duration of the Company’s previous stock option programmes and exercising of options can be found below.

Policies and Charters

Charters

 

Policies

Reporting Compliance Concerns

The Evotec Group provides employees and external stakeholders with EVOwhistle as a channel to report compliance-related concerns such as suspected or observed misconduct, violations of the Evotec Code of Conduct or other legal violations. EVOwhistle is Evotec Group´s dedicated and secure website hosted outside the Evotec Group´s network. It aims to create a trusted system with protection for a Whistleblower and the person, which may be subject of an addressed concern. The link to website is https://evotecgroup.integrityline.org.

Auditors

On 19 June 2019, the Annual General Meeting elected Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft to audit the financial statements and the consolidated financial statements for the fiscal year ending 31 December 2019. Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft has been serving as the Company’s auditor since 2014.

TOP